Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease - Wikidata - awgldk - TriplyDB

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

http://www.wikidata.org/entity/Q36988623

about

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.Big Data Analytics for Genomic Medicine Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation.Atherosclerosis in 2016: Advances in new therapeutic targets for atherosclerosis.Genetics of coronary artery disease: discovery, biology and clinical translation.Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients.Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.It takes a genome to understand a village: Population scale precision medicine.Angiopoietin-like protein 4 and cardiovascular function in COPD.Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.The use of electronic health records for psychiatric phenotyping and genomics.The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities.Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance.Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy.Targeting ApoC-III to Reduce Coronary Disease Risk.Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.Angiopoietin-like 4: A molecular link between insulin resistance and rheumatoid arthritis.Genetic identification of familial hypercholesterolemia within a single U.S. health care system.Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.The Role of Adipocytokines in Coronary Atherosclerosis.Hypertriglyceridaemia and risk of coronary artery disease.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.Electronic health record phenotype in subjects with genetic variants associated with arrhythmogenic right ventricular cardiomyopathy: a study of 30,716 subjects with exome sequencing.Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D.Genetics of Triglycerides and the Risk of Atherosclerosis.We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture.Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets.ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance.ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients.Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes.Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting.Triglycerides and Open Angle Glaucoma - A Meta-analysis with meta-regression.Cardiovascular risk in patients with alpha-1-antitrypsin deficiency.The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding.

P2860

Q30234302-30163237-F416-40C5-A924-597AEE8D1F98 Q30235891-D0B85D3B-F455-41CD-82E2-E501FBA7014E Q30388756-4194CA8F-7F5D-4FA8-A859-D27972DD8A38 Q34549423-E90FF2EE-BDC1-46DB-A646-D9ED72C8B4DA Q34553141-F75C4E8D-7825-487A-9E0D-0F12B0529677 Q36255629-A031B61B-DA16-4272-9C26-77AC0B0D32D3 Q36851336-883CD449-D2E7-46C9-88CA-2FBD97807DAC Q36913493-91CBCEE4-74E3-46C0-8A94-43A0C44E5E2B Q37099337-F7952BEA-5174-4142-9F04-BA2EE028ABC1 Q37398057-E1A8D78B-B657-4F9D-8E95-E85FDAC9731A Q37464058-A3589000-77B6-47C2-9777-73FA994F9715 Q37556343-9B22563C-48D0-4684-A669-2542E9EFDFFC Q38616263-DCA6DF5C-4979-4A69-B8EA-EF31171CD11E Q38756857-47359286-700E-4F35-98D6-FC7623915D4C Q38764871-4219BEAA-D497-4606-822B-4D756BB352E5 Q38784846-368D004D-AE3F-4584-8B75-CDDCD6C6DB2E Q38835108-075650B4-BA6B-421E-866E-04B110A38C4A Q38861823-7A75D37A-1A26-4A3F-BB3F-DC3509FE8BD7 Q38904497-6F3EB61B-DC64-46C9-A662-00F7B7386361 Q38924697-0E13CDE5-26FF-43DC-8542-002559AF807E Q38988157-AF30D9F2-75E3-460D-9FA1-37BFC67CFD71 Q39048436-DC1D280F-87F4-4CBB-946C-81F1DDF6DAB1 Q39070299-BD82A94E-D1E0-43B7-B1F1-F51F56210063 Q39070311-ABA430BA-880F-496F-8A63-DA02B0F9FF7E Q39129323-E101F864-3141-418A-982D-474A85AD6530 Q39181612-6119E497-1EDA-44F3-9F52-CDE34255A401 Q39200940-EE3E8802-A6C9-4676-BAA1-FDD9F6BA2731 Q39283141-060AE1FE-7F61-4B13-964E-CC74FB525ED7 Q39298579-3E14DDAE-6595-4DBB-8B00-20EDBE7118CF Q39324048-5DBEFB84-9A5A-48DB-A4B3-9D54690D24D9 Q39388920-0C767AD4-2E47-4C1E-A9AF-0357B7051BF7 Q39568339-B68D4D7C-BD72-4DCD-A3F7-EDDAEEF7C945 Q40254292-0FC7D751-0DC7-4A0E-83CF-EECA7BDC0C85 Q40476668-D74428EE-A7F7-408E-AA93-B9F18AA9BCDA Q40635839-4CA23239-E46A-4DCB-9EA1-3DEDBC91937E Q40965986-B81A5C28-1193-407D-AB44-E07D4075080C Q41069344-A7379A04-AF93-459F-9766-68A9D847C795 Q41354254-772F44B4-0CB9-463C-ACE6-438B625DD784 Q41717223-2C6CC2B9-A43B-4A7A-9407-8052A46C4A0D Q42355233-30378875-62A9-4B5F-9FD1-F224DD7ABC79

P2860

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

http://www.wikidata.org/entity/Q36988623

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

@en

type

label

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

@en

prefLabel

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

@en

P1433

Q36988623-0A58B63C-65FC-45D7-A0ED-3A1F16D56904

P1476

Q36988623-58C59901-B991-40FB-898E-DF326440AF5F

P2093

Q36988623-1D0EC37C-BF51-4819-88BB-8F2E1FA96AE9

Q36988623-2CDD350B-1776-4436-AFF4-FB4A637E0CC3

Q36988623-320AFA5C-B5DC-4D96-B102-71AC314A13D7

Q36988623-4194E758-B2C4-4119-803B-0A869C04B1DA

Q36988623-42D42876-B69E-4997-B9C5-0C016AC63473

Q36988623-4F6E956D-1BA9-4166-AC84-27BD6617CFCD

Q36988623-5BFFBC47-65E1-4C17-8EB0-1FF09601F840

Q36988623-69057E54-1EA7-43D7-A39C-E6D69D43996D

Q36988623-7BD4767B-55FF-4DFA-BEB0-EF08D646D762

Q36988623-81EBB212-8AD3-4094-BF9A-9A8B71E7218E

P2860

Q36988623-1AEF5787-0E75-4A15-AD19-96EA45A2D802

Q36988623-27EE76BD-1AFB-4530-BBD8-C98FA699696F

Q36988623-2E221BBF-6911-4458-AA2F-43E03624AF91

Q36988623-36FB2B62-38A2-46F1-9125-3EF683B6B8BA

Q36988623-387A9F2E-14FD-472D-ABA4-E998B86C2C3D

Q36988623-3EBF0694-4C97-444F-8188-F02B2BD49E0F

Q36988623-52D580BC-68B0-43CA-B61A-F89AF997D9E8

Q36988623-56E96B1B-28C1-45AA-80EB-3B8D06924881

Q36988623-58AE044D-7423-496C-AB29-28D92E5476FA

Q36988623-5B7C834E-346E-4151-803F-5A250CD53A9A

P304

Q36988623-4F49851C-DF8E-4B86-B517-1FCEC97F3264

P31

Q36988623-2B7B7FCA-0CA9-4158-8003-B3EE2D6B3A3D

P356

Q36988623-3A8001BE-13F0-460B-8A49-F9FECF274505

P407

Q36988623-5BD3ADE3-90AD-49C3-9222-391F5C0F0981

P433

Q36988623-A6760C97-08BA-44DC-AEE5-0FF2C056C441

P478

Q36988623-3AB54A33-9668-457B-9B03-DF236115FEE1

P50

Q36988623-4338F650-7182-4DA9-AE83-58841957C575

Q36988623-5B32289F-6BAF-4DEE-8C55-D95A55985EC9

Q36988623-69447B04-406C-4FE0-BC48-116823C28769

Q36988623-8C85A55A-48BD-4E7C-AE02-54FF4321608F

Q36988623-B0E48F56-830E-4150-94BB-E09656C7D493

P577

Q36988623-D330F82E-A997-4B5B-BEB5-A2559A835805

P698

Q36988623-D75D2301-BD61-4462-817E-5323ACA43B27

P932

Q36988623-6EC3F1E8-F132-452A-BB07-A9F1D868BD92

P356

P1433

The New England Journal of Medicine

P1476

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

@en

P2093

Alexander Lopez

http://www.w3.org/2001/XMLSchema#string

Aris Baras

http://www.w3.org/2001/XMLSchema#string

Charleen Hunt

http://www.w3.org/2001/XMLSchema#string

Colm O'Dushlaine

http://www.w3.org/2001/XMLSchema#string

Cristopher V Van Hout

http://www.w3.org/2001/XMLSchema#string

David Buckler

http://www.w3.org/2001/XMLSchema#string

David H Ledbetter

http://www.w3.org/2001/XMLSchema#string

David J Carey

http://www.w3.org/2001/XMLSchema#string

Frederick E Dewey

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue

Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia

Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase

Common variants associated with plasma triglycerides and risk for coronary artery disease

GCTA: a tool for genome-wide complex trait analysis

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

P304

1123-1133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1510926

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Marylyn D. Ritchie

Alan R. Shuldiner

Andrew J Murphy

Ingrid B Borecki

P577

2016-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26933753

http://www.w3.org/2001/XMLSchema#string

P932

4900689

http://www.w3.org/2001/XMLSchema#string